Cognetivity Neurosciences（CGNS.F）株式概要コグネティヴィティ・ニューロサイエンシズ・リミテッドはテクノロジー企業として活動している。 詳細CGNS.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性0/6配当金0/6リスク分析株式の流動性は非常に低い 最新の財務報告は1年以上前のものである 意味のある時価総額がありません ( $93 )すべてのリスクチェックを見るCGNS.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW487,172 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG487,172 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.00000199.9% 割安 内在価値ディスカウントEst. Revenue$PastFuture-10m99k2016201920222025202620282031Revenue CA$99.0kEarnings CA$13.0kAdvancedSet Fair ValueView all narrativesCognetivity Neurosciences Ltd. 競合他社STRATA Skin SciencesSymbol: OTCPK:SSKNMarket cap: US$2.4kEncisionSymbol: OTCPK:ECIAMarket cap: US$763.0kNuwellisSymbol: NasdaqCM:NUWEMarket cap: US$247.1kLogicMarkSymbol: OTCPK:LGMKMarket cap: US$719.8k価格と性能株価の高値、安値、推移の概要Cognetivity Neurosciences過去の株価現在の株価US$0.00000152週高値US$0.000152週安値US$0.000001ベータ01ヶ月の変化-99.00%3ヶ月変化n/a1年変化n/a3年間の変化-99.90%5年間の変化-99.90%IPOからの変化-99.90%最新ニュースお知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investorお知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.最新情報をもっと見るRecent updatesお知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investorお知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.株主還元CGNS.FUS Medical EquipmentUS 市場7D0%-1.9%-2.0%1Yn/a-18.7%17.2%株主還元を見る業界別リターン: CGNS.FがUS Medical Equipment業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: CGNS.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is CGNS.F's price volatile compared to industry and market?CGNS.F volatilityCGNS.F Average Weekly Movementn/aMedical Equipment Industry Average Movement8.4%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.2%安定した株価: CGNS.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のCGNS.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト2015n/aSina Habibicognetivity.comCognetivity Neurosciences Ltd.はテクノロジー企業として事業を展開している。統合認知アセスメント、認知症の早期診断を可能にする医療、商業、消費者環境で使用する認知検査プラットフォーム、ウェルネスアプリのOptiMindを開発している。前身はUtor Capital Corp.で、2017年12月にCognetivity Neurosciences Ltd.に社名変更した。Cognetivity Neurosciences Ltd.は2015年に法人化され、カナダのバンクーバーに本社を置いている。もっと見るCognetivity Neurosciences Ltd. 基礎のまとめCognetivity Neurosciences の収益と売上を時価総額と比較するとどうか。CGNS.F 基礎統計学時価総額US$93.00収益（TTM）-US$6.17m売上高(TTM)US$70.64k0.0xP/Sレシオ0.0xPER（株価収益率CGNS.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計CGNS.F 損益計算書（TTM）収益CA$98.97k売上原価CA$1.36m売上総利益-CA$1.27mその他の費用CA$7.38m収益-CA$8.64m直近の収益報告Oct 31, 2023次回決算日該当なし一株当たり利益（EPS）0グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0.0%CGNS.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/18 05:30終値2026/06/25 00:00収益2023/10/31年間収益2023/01/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cognetivity Neurosciences Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investor
お知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.
お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.
お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.
お知らせ • Oct 18Cognetivity Neurosciences Ltd. announced that it has received CAD 0.01 million in fundingOn October 17, 2023, Apogee 21 Holdings, Inc. closed the transaction. The transaction included participation from a single investor
お知らせ • Jul 08Cognetivity Neurosciences Ltd. Announces Eisai's Leqembi Approval for the Treatment of Alzheimer's DiseaseCognetivity Neurosciences Ltd. announced that Eisai's Leqembi has achieved full FDA approval for the treatment of Alzheimer's disease, news that brings hope to tens of millions of sufferers and at-risk individuals worldwide. Leqembi received accelerated FDA approval in January 2023 due to its ability to clear amyloid plaques - harmful clumps of protein in the brain associated with Alzheimer's disease. Previously, the U.S. government's Medicare health plan for people aged 65 and over had restricted coverage only to patients in a clinical trial. Standard approval, the first of its kind for Alzheimer's disease, means that Leqembi will now be covered for all patients, although the Centers for Medicare and Medicaid Services (CMS) is linking reimbursement to patient participation in a health agency database, known as a registry. Since Alzheimer's is a disease of aging, most U.S. patients are insured by Medicare. CognICA is being used successfully to screen populations of individuals at risk of mild cognitive impairment, and reliably identifies those who show early signs of cognitive problems and require further assessment. Following clinical diagnosis, the technology platform is used to monitor changes in cognitive function among patients receiving monthly treatment, demonstrating the ability to deliver the CMS mandated reporting on patient progress. The speed, precision and ability to scale of CognICA give it a unique position in the market for the large-scale detection and monitoring of individuals with early stage Alzheimer's disease and other brain health issues. Cognetivity Neurosciences remains dedicated to utilizing its AI platform technology to transform the landscape of brain health globally, enhance the quality of care provided to patients and to reduce the burden and cost to providers and payers, delivering the company's vision of A Brighter Mind for a Fuller Life.
お知らせ • Feb 16Cognetivity Neurosciences Ltd. Announces Release an Update Version of Its Tool, CognICATMCognetivity Neurosciences Ltd. announced that it has released an updated version of its tool, CognICATM. CognICA is a unique platform for the assessment and monitoring of brain health: powered by artificial intelligence (AI), FDA-registered and CE-marked, and commercially deployed in North America, East and Southeast Asia, the Middle East, and the UK's National Health Service (NHS). The company's technology uses AI and machine learning (ML) techniques to help detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measure of brain function. This enables CognICATM to facilitate the early identification of individuals with brain health issues, at a time when interventions are most effective, as well as supporting their long-term treatment management and monitoring. Crucially, as a fundamentally AI and ML-based tool, CognICA can be continually expanded and enhanced over time, trained on more data from an increasing number of global deployments to build increasingly refined, disease-specific models. In the case of Alzheimer's disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of core biomarkers of neurodegeneration in the brain, such as amyloid (A) protein. The tool is tablet-based, self-administered and independent of language and education biases, thereby making it highly effective for comprehensive, scaled screening programs in all geographies. Among a range of improvements, the latest version of CognICA includes local data storage functionality, facilitating deployment in an expanded range of territories and thus enlarging the potential market for the technology. It also permits unlimited scaling, ensuring that users benefit from a rapid, efficient experience regardless of user load.
お知らせ • Jan 25Cognetivity Neurosciences Ltd.'s CognICA Platform Successfully Monitors Cognitive Performance in Alzheimer's Patients Receiving Disease- Modifying TherapyCognetivity Neurosciences Ltd. announced that its CognICA tool has demonstrated effectiveness in tracking cognitive function during the treatment of Alzheimer's disease patients with the disease-modifying therapy Aduhelm (aducanumab), manufactured by Biogen. CognICA was used in clinical practice at Mediclinic Parkview Hospital in Dubai, UAE, to screen 108 patients coming into the neurology clinic for cognitive impairment. The tool was then used to monitor the cognition of the patients who received a diagnosis of Alzheimer's disease and were eligible for treatment with Aduhelm, a US Food and Drug Administration (FDA)-approved drug that directly targets amyloid beta pathology. The results showed that patients who received Aduhelm did not show cognitive decline, with two patients showing a significant improvement in cognitive performance. They demonstrate the use of CognICA as a sensitive screening and monitoring tool to support detection of cognitive impairment and measure changes in cognitive performance in response to disease-modifying therapies for Alzheimer's. As such, the tool is perfectly suited to support the dawning era of targeted therapies forneurodegenerative disease as evidenced by the FDA's approval, in the first week of 2023, of a second drug directly targeting amyloid beta pathology, LeqembiTM (lecanemab). Early detection and diagnosis will be critical to the rapid, large-scale rollout of this family of therapeutics since they havebeen approved for early-stage disease, in the form of mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Outstanding sensitivity to early-stage disease the ability to identify changes in the brain is CognICA's greatest strength, as demonstrated in thousands of patients and numerous peer-reviewed publications.
